NCT04302025 2026-03-06A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)Genentech, Inc.Phase 2 Recruiting99 enrolled
NCT07449754 2026-03-04Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant MelanomaHanmi Pharmaceutical Company LimitedPhase 2 Recruiting45 enrolled
NCT04835805 2026-02-03A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.Genentech, Inc.Phase 1 Active not recruiting65 enrolled
NCT04109456 2026-01-15IN10018 Monotherapy and Combination Therapy for Metastatic MelanomaInxMed (Shanghai) Co., Ltd.Phase 1 Completed51 enrolled